Read this first. Manjistha is widely sold as a skin and "blood cleansing" supplement, and most writing about it does not mention the following: it belongs to a plant family whose anthraquinone compounds have shown carcinogenic potential in animal studies, and the closely related European madder is banned in food supplements across the EU on genotoxicity grounds. That does not make manjistha dangerous to touch, and it is not a reason to panic if you have used it. It is a reason to treat internal use as a decision for a qualified practitioner rather than a self-prescribed wellness habit. The safety section below is the most important part of this page.
What is Manjistha?
Manjistha is a climbing perennial of the madder family, native to the Himalayan foothills and found across India, Sri Lanka, Japan and parts of Africa. Its name means "bright red", after the dye its roots yield - the same reason its European cousin, Rubia tinctorum, was cultivated for centuries as a textile colourant.
In Ayurveda it is the pre-eminent raktashodhaka, a herb that acts on rakta dhatu - the blood tissue. Because Ayurvedic reasoning treats skin as closely dependent on the quality of blood, a herb that acts on blood is expected to show up in the complexion. That is why manjistha appears in almost every traditional formula aimed at pigmentation, uneven tone, and skin described as "heated".
It is also classified as varnya, meaning complexion-improving, which is a specific classical category rather than a marketing description.
Traditional Uses
Skin and complexion. The dominant use. Manjistha is taken internally as powder or decoction, and applied externally in pastes and oils, for pigmentation, dullness, and inflammatory skin conditions.
Blood purification. The classical framing for a wide range of conditions understood as rakta dushti - impurity of the blood - which historically covered skin disease, some bleeding disorders, and inflammatory conditions.
Gynaecological use. Traditional formulas use it for irregular or heavy menstrual bleeding. The 2022 pharmacological review notes that Chinese and Ayurvedic prescriptions containing R. cordifolia have been used clinically for abnormal uterine bleeding and dysmenorrhoea.
Lymphatic support. A more modern Western-Ayurvedic framing, common in supplement marketing, with a thinner classical basis than the blood-purification use.
What Modern Research Suggests
The phytochemistry is well characterised. More than 100 compounds have been isolated from R. cordifolia, of which the anthraquinones are the signature class - around 28 identified, including purpurin, munjistin, rubiadin, alizarin and xanthopurpurin. Purpurin is generally the most abundant.
There is a real mechanism behind the complexion claim. Purpurin inhibits tyrosinase, the rate-limiting enzyme in melanin production. That is the same enzyme targeted by conventional skin-brightening ingredients, so the traditional use is at least mechanistically coherent rather than arbitrary.
But the mechanism is laboratory work, not clinical evidence. Tyrosinase inhibition in a test tube is a long way from measurable change in human pigmentation, and that gap is where most botanical skincare marketing lives. No controlled human trial supports manjistha for skin tone, topically or internally.
Other pharmacological activity is preclinical. Antioxidant, anti-inflammatory, antiplatelet and antitumour effects have been reported, essentially all in cell and animal models.
The evidence base has a specific hole in it. The most comprehensive review to date (Wen and colleagues, 2022) states directly that there are few pharmacokinetic and toxicity studies of R. cordifolia, and that clinical safety data for it is lacking. For a herb sold widely as a daily supplement, that absence matters more than any of the promising preclinical results.
Safety and Precautions
This is the section that distinguishes manjistha from the other herbs in this collection, and it deserves to be read in full.
The anthraquinone problem
The compounds that give madder plants their colour are also the compounds that carry the safety concern.
- Rubiadin and alizarin, both present in manjistha, showed carcinogenic potential in rodents. Inoue and colleagues (2009) fed male rats 0.04% rubiadin in a medium-term multi-organ bioassay and found significantly increased atypical renal tubules and hyperplasias, and induced renal cell adenomas and carcinomas. Rubiadin also affected liver and colon. Alizarin produced similar but weaker kidney effects.
- Madder root itself is carcinogenic in long-term rodent feeding. Westendorf and colleagues (1998) gave rats 1% or 10% madder root for 780 days and found dose-dependent increases in benign and malignant liver and kidney tumours, with DNA adducts in liver, kidney and colon, attributed to the anthraquinone lucidin.
- Madder extract is banned in food and food supplements in the European Union on genotoxicity grounds.
The important caveat, stated fairly
Most of that work concerns Rubia tinctorum, European madder, not Rubia cordifolia. They are different species. The 2009 study tested isolated compounds rather than either whole plant - but rubiadin and alizarin are both present in manjistha, so the concern travels with the chemistry rather than with the species name.
What does not exist is direct long-term safety data on R. cordifolia. That is not reassurance. An absence of evidence of harm in a plant whose close relative is banned as a food supplement is a reason for caution, not confidence.
Practical position
- Topical use is a different exposure route and is generally well tolerated. Skin absorption of these compounds is limited compared with eating them daily. Patch test any new preparation.
- Internal use should be a practitioner's decision, at a defined dose, for a defined period - not an indefinite daily supplement taken on the strength of a product description.
- Avoid internally in pregnancy and breastfeeding. Insufficient data, and the herb has traditional emmenagogue use.
- Avoid with kidney or liver disease, given where the rodent tumours appeared.
- It stains. Skin, cloth, and sometimes urine, which is harmless but startling if unexpected.
None of this means manjistha is unsafe in a face oil. It means the daily-capsule use case deserves a conversation that the supplement aisle is not having.
Preparation and Dosage
Topical. Manjistha powder mixed into a paste with rose water, honey or yoghurt as a face mask, or bought already infused into a face oil. This is the lowest-risk way to use it and the one most aligned with the complexion claim.
Internal. Traditional doses run roughly 1 to 3 grams of powder daily, or as a decoction, usually as part of a compound formula rather than alone. Given the safety picture above, this is not something to start without a qualified Ayurvedic practitioner who knows your history, and it is not something to take indefinitely.
Frequently Asked Questions
Is manjistha safe? Topically, for most people, yes - patch test and watch for irritation. Internally, the honest answer is that nobody knows, because the long-term toxicity studies on this species have not been done, and its chemical relatives have a poor safety record. That uncertainty should drive the decision.
Does it actually even out skin tone? There is a plausible mechanism - purpurin inhibits tyrosinase, the key enzyme in melanin production - but no human trial demonstrates the effect. Treat it as traditional use with an interesting mechanism, not a proven result.
Is it the same as madder root? Related, not the same. Manjistha is Rubia cordifolia, Indian madder. Madder root usually means Rubia tinctorum, the European dye plant, which is the one banned in EU food supplements. They share several anthraquinones.
Why does everyone else call it a safe blood purifier? Because the classical literature does, and because the toxicology sits in journals rather than in product copy. Both things can be true: a long traditional record, and a modern safety question that has not been resolved.
Can I use it while pregnant? Not internally. Insufficient safety data and traditional emmenagogue use are enough on their own; the anthraquinone question makes it clearer.
Sources and Evidence
- Wen M, Chen Q, Chen W, Yang J, Zhou X, Zhang C, Wu A, Lai J, Chen J, Mei Q, Yang S, Lan C, Wu J, Huang F, Wang L (2022). "A comprehensive review of Rubia cordifolia L.: Traditional uses, phytochemistry, pharmacological activities, and clinical applications." Frontiers in Pharmacology 13: 965390. doi:10.3389/fphar.2022.965390
- Inoue K, Yoshida M, Takahashi M, Fujimoto H, Shibutani M, Hirose M, Nishikawa A (2009). "Carcinogenic potential of alizarin and rubiadin, components of madder color, in a rat medium-term multi-organ bioassay." Cancer Science 100(12): 2261–2267. doi:10.1111/j.1349-7006.2009.01342.x
- Westendorf J, Pfau W, Schulte A (1998). "Carcinogenicity and DNA adduct formation observed in ACI rats after long-term treatment with madder root, Rubia tinctorum L." Carcinogenesis 19(12): 2163–2168. doi:10.1093/carcin/19.12.2163
Sources 2 and 3 concern isolated anthraquinones and Rubia tinctorum respectively, not Rubia cordifolia directly. Source 1 confirms that comparable toxicity and clinical safety data for Rubia cordifolia has not been generated.
